Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 9/2014

01-09-2014 | Image of the Month

Diuretic 18 F-FDG PET/CT for therapy monitoring in urothelial bladder cancer

Authors: Elodie Coquan, Charline Lasnon, Florence Joly, Jean-Marc Lefort, Nicolas Aide

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2014

Login to get access

Excerpt

Until recently, 18 F-FDG PET/CT had not been widely used in the management of bladder cancer because of renal excretion of 18 F-FDG hampers primary tumour visualization. A recent prospective study demonstrated that forced diuresis significantly improved detection of bladder tumours [1]. As 40 % of bladder cancer patients do not respond to neoadjuvant chemotherapy, there is a need to identify them early in the course of treatment [2]. …
Literature
1.
Nayak B, Dogra PN, Naswa N, Kumar R. Diuretic 18 F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique. Eur J Nucl Med Mol Imaging. 2013;40:386–93.PubMedCrossRef
2.
Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66.PubMedCrossRef
3.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–50S.PubMedCentralPubMedCrossRef
4.
Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.PubMedCentralPubMedCrossRef
Metadata
Title
Diuretic 18 F-FDG PET/CT for therapy monitoring in urothelial bladder cancer
Authors
Elodie Coquan
Charline Lasnon
Florence Joly
Jean-Marc Lefort
Nicolas Aide
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-014-2800-0

Other articles of this Issue 9/2014

European Journal of Nuclear Medicine and Molecular Imaging 9/2014 Go to the issue

Original Article

Myocardial perfusion imaging for predicting cardiac events in Japanese patients with advanced chronic kidney disease: 1-year interim report of the J-ACCESS 3 investigation

Original Article

A prediction model for 5-year cardiac mortality in patients with chronic heart failure using 123I-metaiodobenzylguanidine imaging

Book Review

Jean-François H. Geschwind and Michael D. Dake (Eds): Abrams’ Angiography: Interventional Radiology, 3rd edn

Original Article

The value of 18F-FDG PET/CT in the management of malignant peripheral nerve sheath tumors

Society Communications

Modern radiopharmaceutical solutions and up-to-date technologies, at the 3rd Balkan Congress of Nuclear Medicine

Original Article

Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs